FDA Drug Approval Summaries: Pemetrexed (Alimta®)

FDA Drug Approval Summaries: Pemetrexed (Alimta®) Maitreyee Hazarika, Robert M. White, John R. Johnson, Richard Pazdur Oncologist 2004; 9: 482-488 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine and FDA information, and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the mechanism of action of a recently approved new cancer drug, pemetrexed. Describe the adverse-event profile of pemetrexed and a novel approach for toxicity reduction. Discuss the rationale for the FDA approval of pemetrexed. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 11, 2004 Most Recent Review: Oct. 11, 2004* Most Recent Update: Oct. 11, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.